Department Of Rheumatology
Anca Askanase, MD, MPH

Dr. Anca Dinu Askanase recently joined the CUMC Rheumatology faculty where she is the founder and clinical director of Columbia's new Lupus Center and the Director of Rheumatology Clinical Trials. Dr. Askanase is an internationally renowned clinician, diagnostician and researcher with more than 15 years specializing in complex Systemic Lupus Erythematosus (SLE). Dr. Askanase trained as a rheumatologist at New York University where she remained for more than 15 years on faculty, directing clinical trials, training fellows and residents, and treating challenging cases of SLE at NYU's prestigious Hospitals.

Dr. Askanase's academic career has focused primarily on the care of patients with SLE and other autoimmune diseases.In order to provide better care for patients suffering from these devastating diseases, she embarked on a journey of research and discovery, with the goal of understanding disease outcomes from both the patients' and physicians' perspective while helping to redefine 21st century therapeutic options. It is Dr. Askanase's hope that by helping to establish widely accepted parameters for quantifying the impact of the disease and the response to medications, all doctors will have effective benchmarks and therapeutic options to better treat patients with SLE's often confounding symptoms.

In addition to numerous publications and benchmark clinical trials, Dr. Askanase is a member of the two major international consortia aimed at providing the collaboration between lupus doctors needing to improve outcomes and therapies in Lupus: the SLICC (SLE international Collaborating Clinics) and the LNTN (Lupus Nephritis Trial Network).Dr. Askanase believes that excellent care often involves bringing novel therapies to her patients with Lupus and other autoimmune diseases; thus, she has been involved in every major SLE clinical drug trial and multiple NIH and industry sponsored clinical trials. One of her most rewarding experiences was her involvement as the Site Principal Investigator in the registrational study that led to the FDA approval of Belimumab, the first new Lupus drug in over 50 years. Dr. Askanase also designed and executed the only study looking at a rational approach (based on pharmacogenetics and metabolite measurement) to use Azathioprine in the treatment of Lupus. She is currently evaluating the use of ACTH as a steroid alternative in lupus nephritis. Dr. Askanase is also a proud Columbia Alumnus and still lives in Morningside Heights with her husband and two children.

Clinical Studies Managed By This Investigator:
Condition Study Title
Lupus [ CLOSED ] A study for subjects with Lupus nephritis using an oral study drug MLN9708
Lupus [ CLOSED ] A study on subjects with systemic lupus erythematosus using study drug CC-220
Lupus [ CLOSED ] A study for patients with Systemic Lupus Erythematosus using study drug ALX-0061
Lupus [ CLOSED ] A study for patients with lupus nephritis using the study drug Obinutuzumab.
Lupus [ CLOSED ] A study for patients with Lupus Nephritis using the study drug BI 655064.
Lupus [ CLOSED ] A study for patients with Lupus using study drug ustekinumab
Lupus [ CLOSED ] A study for patients with lupus using the study drug XmAb5871.
Autoimmune Disorders [ CLOSED ] A study for patients with lupus nephritis, using an investigational treatment design with rituximab, cyclophosphamide, and solumedrol
Lupus [ CLOSED ] Study of Experimental Gel Drug in Subjects with Persistently Active Systemic Lupus Erythematosus (SLE)
COVID-19 (Coronavirus) [ CLOSED ] Chloroquine Prophylaxis (Prevention) for NewYork-Presbyterian Hospital (NYP) Health Care Workers at Risk for COVID-19